



# Sunitinib

Nierenzellkarzinom (Hypernephrom) » fortgeschritten »  
Erstlinientherapie

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

## **Herausgeber**

DGHO Deutsche Gesellschaft für Hämatologie und  
Medizinische Onkologie e.V.  
Bauhofstr. 12  
10117 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Andreas Hochhaus

Telefon: +49 (0)30 27 87 60 89 - 0

[info@dgho.de](mailto:info@dgho.de)

[www.dgho.de](http://www.dgho.de)

## **Ansprechpartner**

Prof. Dr. med. Bernhard Wörmann  
Medizinischer Leiter

## **Quelle**

[www.onkopedia.com](http://www.onkopedia.com)

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

# Inhaltsverzeichnis

<b>1 Sunitinib, RCC, advanced, first line, intermediate/high risk .....</b>	<b>2</b>
---	----------

# Sunitinib

**Dokument:** Fact Sheet

**Spezifizierung:** Nierenzellkarzinom (Hypernephrom) » fortgeschritten » Erstlinientherapie

**Stand:** Mai 2020

## 1 Sunitinib, RCC, advanced, first line, intermediate/high risk

**Sunitinib, RCC, advanced, first line, intermediate/high risk**

onkopedia				Facts	Appraisal																																															
<b>Parameter</b>	<b>Results<sup>8</sup></b>	<b>HR<sup>9</sup></b>	<b>p value</b>	<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 10%;"></td> <td style="width: 10%; text-align: center;">5</td> <td style="width: 10%; text-align: center;">4</td> <td style="width: 10%; text-align: center;">3b</td> <td style="width: 10%; text-align: center;">3a</td> <td style="width: 10%; text-align: center;">2c</td> <td style="width: 10%; text-align: center;">2b</td> <td style="width: 10%; text-align: center;">2a</td> <td style="width: 10%; text-align: center;">1b</td> <td style="width: 10%; text-align: center;">1a</td> </tr> <tr> <td>Evidence (LoE)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td style="width: 10%;"></td> <td style="width: 10%; text-align: center;">1</td> <td style="width: 10%; text-align: center;">2</td> <td style="width: 10%; text-align: center;">3</td> <td style="width: 10%; text-align: center;">4</td> <td style="width: 10%; text-align: center;">5</td> <td colspan="4"></td> </tr> <tr> <td>Clinical benefit (ESMO MCBS)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: yellow;"></td> <td style="background-color: #cccccc;"></td> <td colspan="4"></td> </tr> <tr> <td colspan="2"></td> <td colspan="2"> <div style="display: flex; align-items: center; gap: 5px;"> <span style="width: 10px; height: 10px; background-color: blue; border: 1px solid black; margin-right: 5px;"></span> curative                             <span style="width: 10px; height: 10px; background-color: yellow; border: 1px solid black; margin-left: 20px; margin-right: 5px;"></span> non-curative                         </div> </td> <td colspan="3"></td> </tr> </table>			5	4	3b	3a	2c	2b	2a	1b	1a	Evidence (LoE)											1	2	3	4	5					Clinical benefit (ESMO MCBS)												<div style="display: flex; align-items: center; gap: 5px;"> <span style="width: 10px; height: 10px; background-color: blue; border: 1px solid black; margin-right: 5px;"></span> curative                             <span style="width: 10px; height: 10px; background-color: yellow; border: 1px solid black; margin-left: 20px; margin-right: 5px;"></span> non-curative                         </div>				
	5	4	3b			3a	2c	2b	2a	1b	1a																																									
Evidence (LoE)																																																				
	1	2	3			4	5																																													
Clinical benefit (ESMO MCBS)																																																				
		<div style="display: flex; align-items: center; gap: 5px;"> <span style="width: 10px; height: 10px; background-color: blue; border: 1px solid black; margin-right: 5px;"></span> curative                             <span style="width: 10px; height: 10px; background-color: yellow; border: 1px solid black; margin-left: 20px; margin-right: 5px;"></span> non-curative                         </div>																																																		
<b>RR<sup>2</sup></b>	<b>12</b> vs <b>47</b>		p < 0.001																																																	
<b>PFS<sup>3</sup></b>	<b>5</b> vs <b>11</b>		p < 0.001																																																	
<b>OS<sup>5</sup></b>	<b>21.8</b> vs <b>26.4</b>	<b>0,82</b>	p = 0.051																																																	
<b>SAE<sup>7</sup></b>			p = 0.05																																																	
<b>Patients</b>	advanced/metastatic, all risk groups <sup>15</sup>																																																			
<b>Trial</b>	SU011248, phase 3																																																			
<b>Randomisation</b>	1 : 1																																																			
<b>N<sup>1</sup></b>	750																																																			
<b>New Therapy</b>	Sunitinib																																																			
<b>Control</b>	Interferon alpha																																																			
<b>Publication</b>	DOI:10.1056/NEJMoa065044; DOI:10.1200/JCO.2008.20.1293																																																			

Legende:

<sup>1</sup> N - number of patients

<sup>2</sup> RR - remission rate, in %

<sup>3</sup> PFS - progression-free survival in months

<sup>5</sup> OS - overall survival in months

<sup>7</sup> SAE - serious adverse events, CTCAE grade 3/4

<sup>8</sup> results for control, results for new therapy

<sup>9</sup> hazard ratio for new therapy

<sup>15</sup> Memorial Sloan Kettering Cancer Center Score (Motzer Score)